External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease

External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease

Infliximab is approved for treatment of various chronic inflammatory diseases including inflammatory bowel disease (IBD). However, high variability in infliximab trough levels has been associated with diverse response rates. Model-informed precision dosing (MIPD) with population pharmacokinetic mode...

Full description

Bibliographic Details
Main Authors: Christina Schräpel, Lukas Kovar, Dominik Selzer, Ute Hofmann, Florian Tran, Walter Reinisch, Matthias Schwab, Thorsten Lehr
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Pharmaceutics
Subjects:
infliximab
population pharmacokinetics
inflammatory bowel disease
model-informed precision dosing
dose individualization
Online Access:https://www.mdpi.com/1999-4923/13/9/1368

Internet

https://www.mdpi.com/1999-4923/13/9/1368

Similar Items